Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 6, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 334,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,494.9403 pence per share.
- Transaction Date: June 6, 2006.
Material Changes
Following the repurchase, the Company's share capital structure changed as follows:
- Treasury Shares: The Company now holds 169,541,678 shares in Treasury.
- Shares in Issue: There are 5,812,830,088 shares in issue (excluding Treasury shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the specific share repurchase announcement. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 334,000 shares purchased at 1,494.9403 pence per share.
- Confirm the updated total number of shares in issue (5,812,830,088) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.